Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer
Mr. Sitar will be responsible for developing and implementing Innovate’s financial strategy and working with the CEO to further the company’s mission and continue its growth plans. Most recently, Mr. Sitar was the chief financial officer of
Innovate’s Chief Executive Officer,
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in nonalcoholic steatohepatitis (
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions and are based on Innovate’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements related to the development of our drug candidates, our operations and business strategy, our plans with respect dilutive and non-dilutive capital raising, changes to our management team and other corporate updates. Actual results may differ materially from those expressed by the forward looking statements in this press release due to the substantial risks and uncertainties associated with these forward looking statements, including, among others, risks related to our ability to obtain additional capital on favorable terms or at all, whether through out-licensing arrangements or otherwise, and the success, timing and cost of our drug development programs and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, the risks that prior clinical and preclinical results may not be replicated and the risks that we may not obtain sufficient funding for these trials, including, among others, our Phase 3 trial for INN-202. These risks and uncertainties include, but may not be limited to, those described in our Annual Report on Form 10-K filed with the SEC on March 18, 2019, and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Source: Innovate Biopharmaceuticals, Inc